Dalbavancin for infective endocarditis: A systematic review of effectiveness, safety, and dosing
Dalbavancin demonstrates high cure rates and excellent tolerability in IE, and could offer an attractive alternative to conventional prolonged intravenous therapy. Further randomized controlled trials are warranted to define standardized protocols.
Authors
- Andreas G. Tsantes (ORCID: https://orcid.org/0000-0002-3695-0759)
- Stella Baliou (ORCID: https://orcid.org/0000-0001-9988-777X)
- P. Ioannou
- Sotirios P. Fortis (ORCID: https://orcid.org/0000-0003-1739-9225)
- Deny Tsakri (ORCID: https://orcid.org/0009-0003-1978-5864)
- Marianna Vlachaki
- Rozeta Sokou
- George Samonis
- Alexandra Mpakosi
- Vasilios Petrakis
- Anastasios E Chaldoupis
- Aglaia Domouchtsidou
- Konstantina A Tsante
- Gerasimos Siasos
Institutions
- Humanitas University (IT)
- University of Crete (GR)
- National and Kapodistrian University of Athens (GR)
- University of West Attica (GR)
- Aretaeio Hospital (GR)
- St Savas Hospital (GR)
- General Hospital of Nikea (GR)
- Metropolitan Hospital (GR)
- University Hospital of Alexandroupolis (GR)
- IRCCS Humanitas Research Hospital (IT)
- Sotiria General Hospital (GR)
Publication Details
- Journal
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1007/s10096-026-05434-3
- Primary Topic
- Infective Endocarditis Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00